1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Alzheimer's Rollercoaster: Azeliragon Misses Endpoints, But Responding Subgroup Identified

 
• By John Davis

US biotech vTv Therapeutics has again reported disappointing top-line Phase III clinical study results for its potential Alzheimer's disease therapy, azeliragon, but believes it has identified a possible path to continued development.

Brain
• Source: Shutterstock

The second part of the STEADFAST Phase III study of vTv Therapeutics Inc.'s potential Alzheimer's disease therapy, azeliragon - Part B in ex-US patients - has arrived at similar negative top-line results as Part A in US patients, leading to a 21% fall in the US biotech's stock price on Nasdaq on June 12.

Investors thus signaled their disappointment despite vTv Therapeutics suggesting it had identified a subgroup of patients in whom azeliragon appeared to have therapeutic promise. The results announcement follows a series of similar negative outcomes from other potential Alzheimer's therapies in late-stage studies, representing something of a rout in this therapeutic sector

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D